54% of referred patients were excluded from the trial and sent directly forward to PCAS because they had a „prohibitive high risk‰. 38 It is unclear who this population might conceivably be, as the risk in the SAPPHIRE trial is low compared to the NASCET and ACE (CEA-) trials.
54% of referred patients were excluded from the trial and sent directly forward to PCAS because they had a „prohibitive high risk‰.38 It is unclear who this population might conceivably be, as the risk in the SAPPHIRE trial is low compared to the NASCET and ACE (CEA-) trials.
